1
|
Hernandez-Ruiz E, Alvarado-Ibarra M, Juan Lien-Chang LE, Banda-Garcia L, Aquino-Salgado JL, Barragan-Ibanez G, Ramirez-Romero EF, Nolasco-Cancino C, Herrera-Olivares W, Morales-Adrian JDJ, Paredes-Lozano EP, Espitia-Rios ME, Gonzalez Lopez-Elizalde MDM, Lopez-Arroyo JL, Trejo-Gomora JE, De la Pena-Celaya JA, Alvarez-Vera JL, Arana-Luna LL, Martinez-Rios A, Resendiz-Olea R, Rodriguez-Velasquez LJ, Zapata-Canto N, Perez-Zuniga JM. Epidemiology and Clinical Characteristics of Non-Hodgkin Lymphoma in Mexico. World J Oncol 2021; 12:28-33. [PMID: 33738003 PMCID: PMC7935617 DOI: 10.14740/wjon1351] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2020] [Accepted: 01/04/2021] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND There is no epidemiological registry in Mexico. The information about the epidemiology in our country is obtained by these types of studies, such as multicentric studies. A lot of improvements in the survival in non-Hodgkin lymphoma patients had occurred in the last 20 years. The access to treatment in these types of pathology could change the prognostic factors in Mexican Mestizos patients. The primary objective of the study was to learn what the most frequent histological varieties of non-Hodgkin lymphoma in Mexico are. The secondary objectives included clinical characteristics, treatments used, treatment response, disease-free survival and overall survival. METHODS A retrospective, descriptive study of consecutive cases was carried out in 14 hospitals across 14 Mexican states with patients diagnosed with non-Hodgkin lymphoma using the World Health Organization (WHO) 2008 criteria. Inclusion criteria included: ≥ 18 years of age, male or female, any clinical stage at diagnosis, who had received any chemotherapy regimen, with a known outcome. Descriptive statistics was performed for all variables, and survival was assessed using Kaplan-Meier curves. RESULTS Totally, 609 patients were enrolled, of which 545 were B-cell lymphomas and 64 were T-cell lymphomas. Median ages were 61 and 50, respectively. B-cell lymphomas were more common in males with 52.1%, and 65.5% of T-cell lymphomas occurred in females. For B-cell lymphomas, the two most frequent histological subtypes were diffuse large B-cell lymphoma in 63.9%, followed by follicular lymphoma at 18%. Meanwhile, 50% of T-cell lymphomas were of the T/natural killer (NK) subtype, and 87.1% of the patients received a CHOP-like regimen. Radiotherapy was given to 31% of B-cell Lymphomas and 46.9% of T-cell lymphomas. Overall survival at 9 years was 84.6% for B-cell lymphomas, and 73.4% for T-cell lymphomas. CONCLUSIONS Diffuse large B-cell lymphoma constitutes the most frequent subtype for B-cell lymphomas in Mexico. The most frequent T-cell lymphoma is the NK/T histological subtype.
Collapse
Affiliation(s)
- Eleazar Hernandez-Ruiz
- Servicio de Hematologia, Hospital Regional de Alta Especialidad, de Oaxaca, Oaxaca, Mexico
- Servicio de Hematologia, Centro Medico Nacional “20 de Noviembre”, ISSSTE, Mexico City, Mexico
- Servicio de Hematologia, Hospital Regional Presidente Juarez de Oaxaca, ISSSTE, Oaxaca, Mexico
| | - Martha Alvarado-Ibarra
- Servicio de Hematologia, Centro Medico Nacional “20 de Noviembre”, ISSSTE, Mexico City, Mexico
| | | | - Luisa Banda-Garcia
- Servicio de Hematologia, Hospital General de Zona No. 11 de Xalapa, Veracruz, Mexico
| | | | | | | | - Cesar Nolasco-Cancino
- Servicio de Hematologia, Hospital Regional Doctor Juan Graham Casasus de Villahermosa, Tabasco, Mexico
- Servicio de Hematologia, Hospital CERACOM, Villahermosa, Tabasco, Mexico
| | | | | | | | | | | | | | | | | | - Jose Luis Alvarez-Vera
- Servicio de Hematologia, Centro Medico Nacional “20 de Noviembre”, ISSSTE, Mexico City, Mexico
| | - Luara Luz Arana-Luna
- Servicio de Hematologia, Centro Medico Nacional “20 de Noviembre”, ISSSTE, Mexico City, Mexico
| | - Annel Martinez-Rios
- Servicio de Hematologia, Hospital Regional Ignacio Zaragoza ISSSTE, Mexico City, Mexico
| | - Rodrigo Resendiz-Olea
- Servicio de Hematologia, Hospital Regional Ignacio Zaragoza ISSSTE, Mexico City, Mexico
| | | | | | - Juan Manuel Perez-Zuniga
- Servicio de Hematologia, Centro Medico Nacional “20 de Noviembre”, ISSSTE, Mexico City, Mexico
- Servicio de Hematologia, Hospital Regional Ignacio Zaragoza ISSSTE, Mexico City, Mexico
| |
Collapse
|
2
|
Vázquez-Rodríguez JG, Ríos-Gutiérrez CD, Paredes-Lozano EP, García-Flores A. [Frequency and maternal complications of the criteria of hemolysis in preeclamptic patients with HELLP syndrome treated in an intensive care unit]. Ginecol Obstet Mex 2016; 84:19-26. [PMID: 27290843] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
BACKGROUND HELLP syndrome is an aggressive form of preeclampsia related with hemolysis and its complications. OBJECTIVE To determine the frequency of the appearance of criteria of hemolysis and maternal complications in preeclamptic patients with HELLP syndrome treated in an intensive care unit. MATERIAL AND METHODS We carried out a cross-sectional study in 50 preeclamptic women with HELLP syndrome admitted to intensive care unit to determine the presence of the following criteria of hemolysis: peripheral blood schistocytes, anemia (hemoglobin ≤ 10 g/dL), lactate dehydrogenase ≥ 600 U/L, indirect bilirubin ≥ 0.6 mg/dL and hemoglobinuria. We also studied maternal complications in patients with lactate dehydrogenase ≥ 600 U/L and positive for schistocytes. Descriptive (mean, median, range, standard deviation) and inferential (Student t test) statistics were used. RESULTS Lactate dehydrogenase ≥ 600 U/L was found in 36%, indirect bilirubin 0.6 mg/dL in 20%, positive schistocytes in 16%, hemoglobinuria in 4% and anemia in 0%. Patients with lactate dehydrogenase ≥ 600 U/L had more clinical and laboratory deterioration as well as prolonged intensive care unit stay (p = 0.0025). Patients positive for schistocytes did not demonstrate adverse effects. CONCLUSION Biochemical criteria of hemolysis were more frequent than schistocytes, hemoglobinuria and anemia. Patients with lactate dehydrogenase ≥ 600 U/L was alterations more serious than patients with positive schistocytes so its usefulness as a biomarker may be higher.
Collapse
|